Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of KRX-0502 (Ferric Citrate) Dose Regimens in Subjects With Non-Dialysis Dependent Chronic Kidney Disease and Iron-Deficiency Anemia

Trial Profile

Study of KRX-0502 (Ferric Citrate) Dose Regimens in Subjects With Non-Dialysis Dependent Chronic Kidney Disease and Iron-Deficiency Anemia

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ferric citrate (Primary)
  • Indications Iron deficiency anaemia
  • Focus Therapeutic Use
  • Acronyms COMPASS
  • Sponsors Akebia Therapeutics; Keryx Biopharmaceuticals
  • Most Recent Events

    • 25 Mar 2021 According to an Akebia Therapeutics media release, data from this trial will be presented at the National Kidney Foundation 2021 Spring Clinical Meetings (NKF SCM21),
    • 09 Oct 2020 According to an Akebia Therapeutics media release, abstract to be presented at ASN Kidney Week are now available online on the ASN Kidney Week abstract portal.
    • 09 Oct 2020 According to an Akebia Therapeutics media release, data from this study will be presented virtually at the American Society of Nephrology Kidney Week 2020 Reimagined (ASN Kidney Week).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top